systemic light-chain AL amyloidosis
Haematology · 2021–2022
2decisions
1medicine
2carried consumer input
21individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| daratumumab In combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD), for the treatment of patients with newly diagnosed systemic light-chain AL… | May 2022 | Recommended | input received Myeloma Australia · Leukaemia Foundation · Australian Amyloidosis Network |
| daratumumab Newly diagnosed patients with systemic light-chain AL amyloidosis, administered in combination with cyclophosphamide, bortezomib and dexamethasone for 24… | Nov 2021 | Not recommended | 21 individuals Myeloma Australia · Leukaemia Foundation · Australian Amyloidosis Network |
Who spoke
Myeloma Australia · Leukaemia Foundation · Australian Amyloidosis Network
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.